MimeCure BV, a start-up based in Groningen, is receiving funding from Pharma Connect Capital to further its groundbreaking research into a new treatment for chronic lung disease. This research began a few years ago as part of co-founder Luke van der Koog’s PhD project in the Pharmacy Department at the University of Groningen.

Pharma Connect Capital B.V. is an investment fund supporting pharmaceutical companies in the Northern Netherlands with capital provided by Investerings Fonds Groningen, Hanzeborg BV (UMCG), NV NOM, the Ir. G.J. Smid Fund, and RUG Ventures.

Promising Initiative

Under the guidance of his PhD advisors, Prof. Reinoud Gosens, Prof. Anika Nagelkerke, and Prof. Erik Frijlink, Van der Koog has developed a new concept that could potentially offer a cure for patients with chronic lung diseases such as COPD. Thanks to the support from Business Generator Groningen, MimeCure was founded, and now, the investment from Pharma Connect Capital provides the resources to expand this research in the coming years.

COPD is a chronic condition in which lung elasticity gradually declines, making breathing increasingly difficult. Until now, COPD, often caused by smoking, has been incurable. MimeCure’s innovation could be a game-changer.

Luke van der Koog, CEO of MimeCure, states, “I am optimistic that with this investment, we can advance our concept and ultimately offer COPD patients a real chance for a cure.” Co-director Prof. Erik Frijlink adds, “In my years at the Department of Pharmacy, I have seen many new drug concepts emerge, but this initiative stands out for its potential to become available to patients.” This sentiment is echoed by Jan Hendriks, director of Pharma Connect Capital: “The science behind this concept is solid, and the enthusiasm, expertise, and experience of MimeCure’s founders made this a worthwhile investment.”

Source: Pharma Connect Capital
Image: Pexels